<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="/allregs/css/uswds.min.css">
    <link rel="stylesheet" href="/allregs/css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="/allregs/index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="/allregs/index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="/allregs/html/titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="/allregs/html/parts/21CFR349.html">Part 349
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 349.70  Labeling of ophthalmic hypertonicity drug products.
                            </h3>
                            <p class="depth1"><em>(a)</em> Statement of identity. The labeling of the product contains the established name of the drug, if any, and identifies the product as a ``hypertonicity'' (select one of the following: ``eye'' or ``ophthalmic'') ``(insert dosage form, e.g., drops).''</p><p class="depth1"><em>(b)</em> Indications. The labeling of the product states, under the heading ``Indications,'' the following phrase: ``For the temporary relief of corneal edema.''</p><p class="depth1"><em>(c)</em> Warnings. In addition to the warnings in Sec. 349.50, the labeling of the product contains the following warnings under the heading ``Warnings'' for products containing any ingredient identified in Sec. 349.16:</p><p class="depth2"><em>(1)</em> ``Do not use this product except under the advice and supervision of a doctor. If you experience eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens or persists, consult a doctor.''</p><p class="depth2"><em>(2)</em> ``This product may cause temporary burning and irritation on being instilled into the eye.''</p><p class="depth2"><em>(3)</em> ``If solution changes color or becomes cloudy, do not use.''</p><p class="depth1"><em>(d)</em> Directions. The labeling of the product contains the following information under the heading ``Directions'': Instill 1 or 2 drops in the affected eye(s) every 3 or 4 hours, or as directed by a doctor.</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
